Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

December 31, 2013

Conditions
Non-small Cell Lung CancerBrain Metastases
Interventions
DRUG

icotinib

"Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.~Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.~Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.~Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity."

RADIATION

Whole brain radiotherapy

Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.

Trial Locations (1)

610041

West China Hospital, Chengdu

All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY